MoonLake Immunotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MLTX and other ETFs, options, and stocks.About MLTX
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases.
CEOJorge Santos da Silva
CEOJorge Santos da Silva
Employees100
Employees100
HeadquartersZug, Zug
HeadquartersZug, Zug
Founded2021
Founded2021
Employees100
Employees100
MLTX Key Statistics
Market cap1.07B
Market cap1.07B
Price-Earnings ratio-4.51
Price-Earnings ratio-4.51
Dividend yield—
Dividend yield—
Average volume2.07M
Average volume2.07M
High today$15.25
High today$15.25
Low today$13.37
Low today$13.37
Open price$13.37
Open price$13.37
Volume4.07M
Volume4.07M
52 Week high$62.75
52 Week high$62.75
52 Week low$5.95
52 Week low$5.95
Stock Snapshot
The current MoonLake Immunotherapeutics(MLTX) stock price is $15.19, with a market capitalization of 1.07B. The stock trades at a price-to-earnings (P/E) ratio of -4.51.
On 2025-12-05, MoonLake Immunotherapeutics(MLTX) stock traded between a low of $13.37 and a high of $15.25. Shares are currently priced at $15.19, which is +13.6% above the low and -0.4% below the high.
The MoonLake Immunotherapeutics(MLTX)'s current trading volume is 4.07M, compared to an average daily volume of 2.07M.
During the past year, MoonLake Immunotherapeutics(MLTX) stock moved between $5.95 at its lowest and $62.75 at its peak.
During the past year, MoonLake Immunotherapeutics(MLTX) stock moved between $5.95 at its lowest and $62.75 at its peak.
Analyst ratings
56%
of 18 ratingsBuy
55.6%
Hold
33.3%
Sell
11.1%
People also own
Based on the portfolios of people who own MLTX. This list is generated using Robinhood data, and it’s not a recommendation.